List of Excipients in Branded Drug AZELASTINE HCL NASAL

Generic Drugs Containing AZELASTINE HCL NASAL

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	azelastine hcl	45802-026	BENZALKONIUM CHLORIDE
Padagis Israel Pharmaceuticals Ltd	azelastine hcl	45802-026	EDETATE DISODIUM
Padagis Israel Pharmaceuticals Ltd	azelastine hcl	45802-026	HYPROMELLOSE
Padagis Israel Pharmaceuticals Ltd	azelastine hcl	45802-026	SODIUM CITRATE
Padagis Israel Pharmaceuticals Ltd	azelastine hcl	45802-026	SORBITOL

What are the Most Frequently-Used Excipients in AZELASTINE HCL NASAL?

# Of NDCs	Excipient
2	BENZALKONIUM CHLORIDE
2	EDETATE DISODIUM
2	HYPROMELLOSE
2	SODIUM CITRATE
2	SORBITOL

Azelastine Hydrochloride Nasal Spray: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Azelastine hydrochloride nasal spray is a mature, genericized antihistamine product with limited active-ingredient exclusivity but meaningful opportunities in formulation design, device performance, OTC positioning, and differentiated packaging. The strongest commercial strategies are unlikely to rely on new chemical patents. They are more likely to use formulation, delivery-device, manufacturing, branding, and regulatory advantages.

What is azelastine hydrochloride nasal spray?

Azelastine hydrochloride nasal spray is a topical H1-antihistamine used for seasonal allergic rhinitis, perennial allergic rhinitis, and, in certain products, nonallergic vasomotor rhinitis. U.S. products have been marketed in 0.1% and 0.15% strengths.

Product category	Typical strength	Dose per spray	Market status
Prescription azelastine nasal spray	0.1%	Approximately 137 mcg	Generic and branded products
OTC azelastine nasal spray	0.15%	Approximately 205.5 mcg	Astepro OTC and competing products
Combination nasal products	Varies	Product-specific	Limited commercial presence

Azelastine is administered intranasally, which creates a relatively direct route to the nasal mucosa. The product has a low-cost active pharmaceutical ingredient, established clinical use, and no biologic manufacturing burden. Commercial differentiation therefore depends heavily on patient experience, spray performance, preservative strategy, and channel economics.

What excipients are used in azelastine hydrochloride nasal spray?

The principal excipients reported for azelastine nasal spray products include benzalkonium chloride, disodium edetate, hypromellose, citric acid, dibasic sodium phosphate, sodium chloride, and purified water. Exact concentrations vary by manufacturer and product strength. FDA labeling and DailyMed records should control any product-specific formulation assessment [1, 2].

Excipient	Primary formulation function	Commercial or technical relevance
Benzalkonium chloride	Antimicrobial preservative	Supports multidose packaging but may raise tolerability and chronic-use concerns
Disodium edetate	Chelating agent	Can improve preservative performance and formulation stability
Hypromellose	Viscosity modifier and mucoadhesive aid	Affects residence time, drip, plume, and sensory perception
Citric acid	Buffer component and pH adjuster	Influences stability, comfort, and nasal irritation
Dibasic sodium phosphate	Buffer component	Controls pH and contributes to ionic strength
Sodium chloride	Tonicity adjustment	Helps align formulation osmolality with nasal tissue
Purified water	Vehicle	Controls aqueous formulation quality and microbiological risk

The excipient system is commercially important because a generic product must match the reference product closely enough to support approval while maintaining acceptable performance across viscosity, pH, osmolality, spray pattern, droplet-size distribution, preservative effectiveness, and container-closure compatibility.

Which excipient strategies create commercial opportunities?

The most attractive opportunities involve improving tolerability, preservative design, and dose delivery without materially changing the approved therapeutic profile.

Preservative optimization

Benzalkonium chloride is widely used in multidose nasal sprays, but its presence can be a concern for long-term or frequent users. A preservative-reduced or preservative-free presentation could support premium positioning, particularly for chronic allergic rhinitis and patients who report nasal dryness or irritation.

The main technical challenge is microbiological control. A preservative-free multidose system may require a valve, metering pump, sterile manufacturing process, antimicrobial container, or package design that limits backflow and contamination. Such a product could support new intellectual property around the container-closure system even where the drug formulation itself is difficult to protect.

Mucoadhesive and viscosity control

Hypromellose and related polymers can influence nasal residence time, runoff, and user perception. Increasing viscosity may reduce post-dose drainage, but excessive viscosity can impair atomization, increase throat deposition, or produce an unpleasant sensation.

A commercially useful formulation target is a narrow viscosity range that improves retention without damaging spray performance. Claims directed to polymer concentration, viscosity, pH, osmolality, or spray characteristics may provide a stronger differentiation platform than broad composition claims.

pH and tolerability

Azelastine nasal products use buffered aqueous systems. pH optimization can affect chemical stability, solubility, nasal comfort, and preservative performance. A formulation with reduced sting or lower irritation potential could support adherence claims, although clinical substantiation would be needed for meaningful promotional use.

Tonicity and sensory performance

Sodium chloride concentration affects tonicity and may influence burning, dryness, and post-dose sensation. A formulation that minimizes hypertonicity while maintaining stability and dose uniformity could target pediatric, geriatric, or high-frequency users, subject to applicable labeling and clinical requirements.

What formulations are protected by azelastine patents?

Azelastine’s original active-ingredient and early formulation exclusivity is mature. The primary commercial risk is therefore unlikely to come from a broad, enforceable composition-of-matter patent covering azelastine hydrochloride itself.

Potentially relevant claim categories include:

1. Specific aqueous formulations.
2. Preservative-free or reduced-preservative systems.
3. Polymer-containing formulations.
4. pH, osmolality, or viscosity ranges.
5. Spray pumps and metering systems.
6. Container-closure configurations.
7. Methods of treating allergic or nonallergic rhinitis.
8. Manufacturing processes that improve dose uniformity or stability.

Patent scope must be evaluated claim by claim. A patent directed to a narrow excipient concentration range may not block a formulation using a different polymer, preservative, buffer, or device. A device patent may create commercial leverage even when the active formulation is no longer protected.

When does azelastine nasal spray lose exclusivity?

Azelastine nasal spray has already lost meaningful U.S. market exclusivity for its core prescription formulation. Generic products have entered the market, and the active ingredient is not protected by a current composition-of-matter exclusivity position comparable to a newly approved chemical entity.

Exclusivity element	Current commercial significance
New chemical entity exclusivity	Expired or no longer material
Core active-ingredient patent	Mature and generally not the principal barrier
Prescription formulation patents	Product- and patent-specific; generally limited compared with early lifecycle
OTC switch exclusivity	Relevant to the approved OTC product and regulatory pathway
Device or packaging patents	Potentially relevant for differentiated products
Method-of-use patents	May remain relevant only for specific labeled uses and claim scope

The key issue for a new entrant is not whether azelastine is generally off patent. It is whether a proposed product can enter with an approvable formulation and device while avoiding any enforceable patents listed for the relevant reference product.

What is the Orange Book status of azelastine nasal spray?

FDA’s Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Prescription azelastine nasal spray products and their approved generic equivalents should be reviewed by reference-listed drug, dosage form, strength, and application number [3].

A commercial diligence review should distinguish among:

• Prescription azelastine hydrochloride nasal spray.
• OTC azelastine products approved under an NDA.
• Different strengths and dosing instructions.
• Separate reference products and ANDA pathways.
• Listed patents that may apply to formulation, method of use, or device components.

An Orange Book listing does not automatically establish that a patent will block every competing product. The proposed product must be mapped against the patent claims, the applicable certification pathway, and any litigation or settlement history.

Are Paragraph IV challenges relevant to azelastine nasal spray?

Paragraph IV risk is generally lower for a mature genericized product than for a newly launched branded nasal spray, but it can still arise where a later-listed formulation, device, or method-of-use patent is asserted against an ANDA applicant.

For an azelastine nasal spray applicant, the relevant regulatory options may include:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification with a future launch date.
• Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or not infringed.
• A section viii statement for a method-of-use patent when the applicant omits the patented indication from labeling.

The litigation exposure depends on the Orange Book record at filing, the reference product, and the claims being certified. A product with a simple formulation and no novel device may face limited patent litigation but greater price competition.

What patent litigation and settlements affect azelastine nasal spray?

No single current litigation strategy defines the entire azelastine nasal spray market. The product class is mature, and competition is primarily driven by generic pricing, OTC brand recognition, supply reliability, and retail placement.

Any launch diligence should search federal district court dockets, the Federal Circuit, FDA’s Orange Book, and FDA approval records for:

• ANDA litigation involving azelastine hydrochloride nasal spray.
• Claims directed to Astepro or other reference products.
• Settlements imposing delayed generic entry.
• Authorized-generic arrangements.
• Device-related disputes.
• Section viii labeling disputes.

A settlement can be commercially important even when it does not preserve broad patent exclusivity. Delayed entry, launch licenses, supply arrangements, and restrictions on an authorized generic can materially affect market timing.

How strong is the azelastine nasal spray patent estate?

The estate is likely weak for the active ingredient and stronger only in narrow technical areas.

Patent layer	Relative strength	Commercial assessment
Active ingredient	Low	Mature molecule with extensive generic use
Broad aqueous formulation	Low to moderate	Vulnerable to design-around and prior-art challenges
Narrow excipient ranges	Moderate if clinically meaningful	May protect a specific formulation but not the category
Spray-device architecture	Moderate to strong	Depends on claim breadth and supplier control
Preservative-free packaging	Moderate	Can create differentiation if the system is difficult to replicate
Method of use	Low to moderate	Depends on indication, labeling, and enforceability
Manufacturing process	Moderate	More useful for supply advantage than market exclusion

The strongest defensible position would combine a formulation patent, device patent, validated human-factors package, and regulatory exclusivity. A single narrow excipient patent is less likely to produce durable market control.

Which companies are competing in azelastine nasal spray?

Competition includes the original branded manufacturers, generic pharmaceutical companies, contract manufacturers, and consumer-health companies with OTC distribution.

The principal competitive groups are:

• Viatris and other generic manufacturers supplying prescription azelastine.
• Bayer, through the Astepro OTC franchise in the United States.
• Retail and private-label companies using approved generic or OTC supply.
• Contract development and manufacturing organizations with nasal-spray filling and pump capabilities.
• Device suppliers that control metering-pump and container-closure technology.

The competitive advantage of a new entrant will depend on channel access. Prescription generic competition favors low cost and reliable supply. OTC competition favors brand awareness, shelf placement, consumer advertising, package design, and perceived tolerability.

What are the main commercial opportunities?

The most credible opportunities are:

1. A preservative-free or reduced-preservative multidose product.
2. A formulation with improved sensory characteristics and reduced throat drip.
3. A pediatric-friendly or geriatric-friendly package, where permitted by labeling.
4. A premium OTC product with differentiated delivery and packaging.
5. A private-label platform for retailers and pharmacy chains.
6. A combination or co-pack strategy with another allergy product, subject to regulatory requirements.
7. A low-cost, supply-secure generic offering for health systems and government purchasers.
8. A device-led licensing program using an established nasal-spray platform.

Revenue exposure is more likely to arise from volume and channel scale than from high per-unit pricing. The prescription market is exposed to generic erosion and payer substitution. The OTC market has greater pricing flexibility but requires consumer marketing and retail distribution.

What manufacturing and IP barriers affect market entry?

The principal barriers are technical execution and regulatory comparability rather than active-ingredient synthesis.

Manufacturers must control:

• Assay and related substances.
• pH and osmolality.
• Viscosity.
• Microbial limits and preservative effectiveness.
• Delivered-dose uniformity.
• Priming and repriming behavior.
• Spray pattern and plume geometry.
• Droplet-size distribution.
• Container-closure integrity.
• Pump-to-pump consistency.
• Extractables and leachables.
• Stability throughout the labeled shelf life.

Nasal sprays are combination products in practical development terms because the formulation and delivery system jointly determine performance. A formulation that is chemically equivalent but produces a different spray pattern may face development, regulatory, or commercial problems.

How does azelastine compare with intranasal corticosteroids?

Azelastine provides antihistamine activity and can act relatively quickly on allergic symptoms. Intranasal corticosteroids generally have a broader anti-inflammatory role and are often positioned as foundational therapy for allergic rhinitis. Fluticasone, budesonide, and triamcinolone compete directly for OTC shelf space, while combination products compete for patients seeking broader symptom control.

Azelastine’s commercial advantages are rapid perceived action and a familiar antihistamine profile. Its disadvantages include taste, bitter after-drip, sedation concerns in some users, and strong competition from established steroid brands.

Key Takeaways

• Azelastine hydrochloride nasal spray is a mature, genericized product with limited core patent protection.
• The strongest commercial opportunities are in excipient optimization, preservative-free delivery, spray-device performance, and OTC positioning.
• Benzalkonium chloride, hypromellose, buffer components, and tonicity agents are central to product differentiation.
• A formulation patent alone is unlikely to provide durable market control unless supported by device or manufacturing claims.
• Orange Book, FDA labeling, patent litigation, and ANDA certification records must be reviewed by reference product and strength.
• The leading barriers are dose-delivery reproducibility, microbiological control, nasal tolerability, and retail or payer access.
• Revenue potential depends more on distribution, supply reliability, and consumer positioning than on exclusivity for the active ingredient.

FAQs

Can a new azelastine nasal spray use a different preservative?

Yes, but the sponsor must establish microbiological control, stability, compatibility, dose uniformity, and regulatory comparability. A preservative change can create a meaningful formulation differentiation opportunity.

Is benzalkonium chloride necessary in azelastine nasal spray?

No. It is used in many multidose aqueous nasal sprays, but alternative preservation or preservative-free delivery systems may be possible if the package and manufacturing process control contamination risk.

Can hypromellose create patent protection for azelastine nasal spray?

Potentially, if claims are directed to a novel concentration range, viscosity profile, performance parameter, or therapeutic result supported by adequate data. Broad use of hypromellose is unlikely to provide strong protection by itself.

Is azelastine nasal spray eligible for an OTC launch?

An OTC launch requires an appropriate FDA regulatory pathway, compliant labeling, acceptable dosing instructions, and support for safe consumer use. The OTC status of one azelastine product does not automatically authorize every strength or formulation.

What is the best licensing asset in azelastine nasal spray?

A validated preservative-free multidose device or a nasal-spray platform with superior dose delivery is likely to be more valuable than a conventional azelastine formulation. Device, manufacturing, and human-factors data can support licensing across multiple nasal products.

References

1. U.S. Food and Drug Administration. (n.d.). Azelastine hydrochloride nasal spray prescribing information. FDA.

2. National Library of Medicine. (n.d.). DailyMed: Azelastine hydrochloride nasal spray. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.

5. United States Pharmacopeia. (n.d.). General chapter <61> Microbiological examination of nonsterile products: Microbial enumeration tests. United States Pharmacopeial Convention.